Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Nordic Nanovector ASA - Extraordinary General Meeting Held


OSLO, Norway, Dec. 20, 2017 /PRNewswire/ --

An Extraordinary General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 20 December 2017 in Oslo, Norway (the "EGM").

All proposals were resolved by the EGM as presented in the notice convening the EGM.

The complete minutes of the EGM are attached to this release and is also available on www.nordinanovector.com.

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com

This information is subject to duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:
Ludvik Sandnes
Chairman
Phone: +47-90-74-30-17
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---extraordinary-general-meeting-held,c2419147

The following files are available for download:

http://mb.cision.com/Public/9819/2419147/90c83538ae792048.pdf

Minutes of EGM 20 12 2017

SOURCE Nordic Nanovector


These press releases may also interest you

at 20:35
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
Media Advisory - Minister Saks in Winnipeg to highlight Budget 2024: Fairness for Every Generation investments to boost research funding in Canada
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Tim Kennedy, and Dan Hollaway
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation Expands Reach to Virginia and Louisiana
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated Revises Time of First Quarter Webcast Teleconference to 7:00 a.m. (ET) on Thursday, May 2, 2024
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...

More news about Health...


News published on and distributed by: